Office-Based Treatment of Opioid-Dependent Patients
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
A 30-year-old man reports a two-year history of heroin use. For the past year, he has been using intranasal heroin every day. He has undergone detoxification twice at a local opioid-abuse treatment program but began using heroin within two days after discharge each time. He has heard of methadone but fears that he will lose his business if he is recognized attending the local program. How should this patient be treated?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment of OUD with B/N has been shown to be medically effective (increasing retention in treatment and decreasing use of illicit opioids) and cost-effective.3–8”
From Implementing Group Visits for Opioid Use Disorder: A Case Series (2020) · cites this paper as [6]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome
Ball, J. C., & Ross, A. O. (1991) · Cited by 903
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Psychiatric and Substance Use Comorbidity Among Treatment-Seeking Opioid Abusers
Brooner, R. K. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130077015 · Cited by 746
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS).
Hubbard, R. L., Craddock, S. G., Flynn, P. M., Anderson, J., & Etheridge, R. M. (1997) · Psychology of Addictive Behaviors · doi:10.1037//0893-164x.11.4.261 · Cited by 602
The Effectiveness of Methadone Maintenance Treatment
Ball, J. C., & Ross, A. (1991) · Springer eBooks · doi:10.1007/978-1-4613-9089-3 · Cited by 590
Effective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
Metzger, D. S., WOODY, G. E., McLellan, A. T., O’Brien, C. P., Druley, P., Navaline, H. A., DePhilippis, D., Stolley, P. D., & Abrutyn, E. (1993) · PubMed · Cited by 530
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415
Research works printed but not linked: 8
- 2001, Fed Regist, 66, 4076
- 2002, Fed Regist, 67, 13114
- AMA home page. Chicago: American Medical Association, 2002. (Accessed August 19, 2002, at http://www.ama-assn.org/.)
- Gowing L, 2000, Cochrane Database Syst Rev, 2, CD002021
- 10.1037/0893-164X.11.4.261 · DOI · Paper page
- Metzger DS, 1993, J Acquir Immune Defic Syndr, 6, 1049
- Salsitz EA, 2000, Mt Sinai J Med, 67, 388
- National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. Bethesda, Md.: National Institutes of Health, 1998. (Accessed August 19, 2002, at http://odp.od.nih.gov/consensus/cons/108/108_intro.htm.) · DOI · Paper page
Cited by
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Self-citationCamí, J., & Farré, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023160 · Cited by 477
Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy
Alford, D. P., Compton, P., & Samet, J. H. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00010 · Cited by 468
Opioid dependence and addiction during opioid treatment of chronic pain
Ballantyne, J. C., & LaForge, S. K. (2007) · Pain · doi:10.1016/j.pain.2007.03.028 · Cited by 447
Dhalla, I. A., Mamdani, M. M., Sivilotti, M. L. A., Kopp, A., Qureshi, O., & Juurlink, D. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090784 · Cited by 438
Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review
A. Yokell, M., D. Zaller, N., C. Green, T., & D. Rich, J. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104010028 · Cited by 398
“Office-based therapy provides additional benefits, including minimization of contact with other drug users and of the stigma associated with drug dependence [21, 38].”
BackgroundPerioperative Management of Acute Pain in the Opioid-dependent Patient
Mitra, S., Sinatra, R. S., & Warltier, D. C. (2004) · Anesthesiology · doi:10.1097/00000542-200407000-00032 · Cited by 301
Barriers to Primary Care Physicians Prescribing Buprenorphine
Hutchinson, E., Catlin, M., Andrilla, C. H. A., Baldwin, L.-M., & Rosenblatt, R. A. (2014) · The Annals of Family Medicine · doi:10.1370/afm.1595 · Cited by 289
Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.541 · Cited by 267
Nunn, A., Zaller, N., Dickman, S., Trimbur, C., Nijhawan, A., & Rich, J. D. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.06.015 · Cited by 264
“…criminal activities (Gordon et al., 2008; Kinlock et al., 2008b), recidivism, and increased participation in drug treatment programs (Gordon et al., 2008; Kinlock et al., 2002; Kinlock et al., 2008b) Buprenorphine is an ORT that acts as a partial opioid agonist (Fiellin and O'Connor, 2002).”
BackgroundImproving general medical care for persons with mental and addictive disorders: systematic review
Druss, B. G., & von Esenwein, S. A. (2006) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2005.10.006 · Cited by 260
Altice, F. L., Bruce, R. D., Lucas, G. M., Lum, P. J., Korthuis, P. T., Flanigan, T. P., Cunningham, C. O., Sullivan, L. E., Vergara-Rodriguez, P., Fiellin, D. A., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209751e · Cited by 256
Self-citationLucas, G. M., Griswold, M., Gebo, K. A., Keruly, J., Chaisson, R. E., & Moore, R. D. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj059 · Cited by 174
The Case for Chronic Disease Management for Addiction
Saitz, R., Larson, M. J., LaBelle, C., Richardson, J., & Samet, J. H. (2008) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318166af74 · Cited by 161
Dick, A. W., Pacula, R. L., Gordon, A. J., Sorbero, M., Burns, R. M., Leslie, D., & Stein, B. D. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1205 · Cited by 159
Lo‐Ciganic, W., Gellad, W. F., Gordon, A. J., Cochran, G., Zemaitis, M. A., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Addiction · doi:10.1111/add.13270 · Cited by 135
Santibanez, S. S., Garfein, R. S., Swartzendruber, A. L., Purcell, D. W., Paxton, L. A., & Greenberg, A. E. (2006) · Journal of Urban Health · doi:10.1007/s11524-005-9009-2 · Cited by 134
Integrating Buprenorphine Treatment into Office-based Practice: a Qualitative Study
Barry, D. T., Irwin, K. S., Jones, E. S., Becker, W. C., Tetrault, J. M., Sullivan, L. E., Hansen, H., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0881-9 · Cited by 139
Self-citationFacilitators and barriers in implementing buprenorphine in the Veterans Health Administration.
Gordon, A. J., Kavanagh, G., Krumm, M., Ramgopal, R., Paidisetty, S., Aghevli, M., Goodman, F., Trafton, J., & Liberto, J. (2011) · Psychology of Addictive Behaviors · doi:10.1037/a0022776 · Cited by 129
Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy
Parran, T. V., Adelman, C. A., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.013 · Cited by 125
“* Corresponding author at: Rosary Hall, 2-West, St. Vincent Charity Hospital, 2351 E. 22nd St. Cleveland, OH 44115, United States.”
InfluentialStein, B. D., Dick, A. W., Sorbero, M., Gordon, A. J., Burns, R. M., LESLIE, D. L., & Pacula, R. L. (2018) · Substance Abuse · doi:10.1080/08897077.2018.1449166 · Cited by 132
“Approval of buprenorphine for treating OUDs was viewed by many as an opportunity to meaningfully expand MT access,(9,32) particularly to those who would not or could not attend methadone clinics for geographical, ideological, or practical considerations.(10,33,34) There was a substantial increase”
BackgroundArfken, C. L., Johanson, C., di Menza, S., & Schuster, C. R. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.05.004 · Cited by 123
“The pharmacological treatment of opioid dependence in an office setting represents a new practice paradigm for U.S. physicians (Fiellin & O'Connor, 2002).”
MethodSinha, R., Kimmerling, A., Doebrick, C., & Kosten, T. R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0640-8 · Cited by 127
Johanson, C., Arfken, C. L., di Menza, S., & Schuster, C. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.019 · Cited by 121
Measurement of QTc in Patients Receiving Chronic Methadone Therapy
Cruciani, R. A., Sekine, R., Homel, P., Lussier, D., Yap, Y. Y., Suzuki, Y., Schweitzer, P., Yancovitz, S. R., Lapin, J., Shaiova, L., et al. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.06.012 · Cited by 115
Paulozzi, L. J., Logan, J. E., Hall, A. J., McKinstry, E., Kaplan, J. A., & Crosby, A. E. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02650.x · Cited by 115
Sullivan, L. E., Chawarski, M., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.12.008 · Cited by 110
Self-citationSupply of buprenorphine waivered physicians: The influence of state policies
Stein, B. D., Gordon, A. J., Dick, A. W., Burns, R. M., Pacula, R. L., Farmer, C. M., Leslie, D. L., & Sorbero, M. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.010 · Cited by 109
“…treatments are available, with opioid antagonist (naltrexone) and opioid agonist (methadone and buprenorphine) medications(Ball & Ross, 1991 ; Fiellin & O’Connor, 2002; Fiellin et al., 2006; Fudala et al., 2003; Johnson et al., 2000; Kakko, Svanborg, Kreek, & Heilig, 2003; Mattick, Kimber,…”
Kissin, W., McLeod, C., Sonnefeld, J., & Stanton, A. (2006) · Journal of Addictive Diseases · doi:10.1300/j069v25n04_09 · Cited by 108
Bruce, R. D., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000219769.89679.ec · Cited by 106
Consensus statement on office-based treatment of opioid dependence using buprenorphine
Fiellin, D. A., Kleber, H. D., Trumble, J. G., McLellan, A. T., & Kosten, T. R. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.06.005 · Cited by 99
Self-citationStein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., LESLIE, D. L., Sorbero, M., Bauhoff, S., Mandell, T. W., & Dick, A. W. (2015) · Milbank Quarterly · doi:10.1111/1468-0009.12137 · Cited by 116
Factors contributing to the rise of buprenorphine misuse: 2008–2013
Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.06.005 · Cited by 95
Monte, A. A., Mandell, T., Wilford, B. B., Tennyson, J., & Boyer, E. W. (2009) · Journal of Addictive Diseases · doi:10.1080/10550880903014767 · Cited by 88
Sporer, K. A. (2004) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2003.11.006 · Cited by 92
“5 The Drug Addiction Treatment Act of 2000, expands the venues for the treatment of opioid dependence in the United States from specially licensed methadone facilities to physicians' private offices, where schedule III to schedule V drugs can be prescribed.(6,7) 8”
BackgroundBuprenorphine: New Tricks With an Old Molecule for Pain Management
Heit, H. A., & Gourlay, D. L. (2008) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e31815ca2b4 · Cited by 95
Clinical Care of the HIV-Infected Drug User
Bruce, R. D., & Altice, F. L. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.03.009 · Cited by 94
Abuse and diversion of buprenorphine sublingual tablets and film
Lavonas, E. J., Severtson, S. G., Martinez, E. M., Bucher‐Bartelson, B., Lait, M. L., Green, J. L., Murrelle, L., Cicero, T. J., Kurtz, S. P., Rosenblum, A., et al. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.02.003 · Cited by 86
“…sublingual formulations in the US is for office-based treatment of opioid dependence, an indication for which its overall safety and effectiveness has been established (Amass et al., 2004; Fiellin & O'Connor, 2002; Johnson, Jaffe, & Fudala, 1992; Mattick, Kimber, Breen, & Davoli, 2008).”
BackgroundTreatment and Prevention of Opioid Use Disorder: Challenges and Opportunities
McCarty, D. W., Priest, K. C., & Korthuis, P. T. (2017) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040617-013526 · Cited by 92
Pharmacological treatments for heroin and cocaine addiction
van den Brink, W., & van Ree, J. M. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.008 · Cited by 100
Friedmann, P. D., Lemon, S. C., Stein, M. D., & D’Aunno, T. A. (2003) · Health Services Research · doi:10.1111/1475-6773.00151 · Cited by 79
Merlo, L. J., Campbell, M. D., Skipper, G. E., Shea, C. L., & DuPont, R. L. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.02.004 · Cited by 79
Weiss, L., Netherland, J. C., Egan, J. E., Flanigan, T., Fiellin, D. A., Finkelstein, R., & Altice, F. L. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820a8226 · Cited by 78
Self-citationPatterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program
Gordon, A. J., Lo-Ciganic, W.-H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000164 · Cited by 76
“As such, this treatment could improve access to opioid agonist therapy among those who are unwilling or unable to receive methadone opioid agonist treatment (Fiellin and O’Connor, 2002; Ducharme and Abraham, 2008).”
BackgroundLucas, G. M. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.09.025 · Cited by 81
“…of those who need treatment, a fact that was employed with success to lobby for legislation passed in 2000 that permits physicians to prescribe schedule III medications (buprenorphine and buprenorphine/naloxone) for the purpose of treating opioid-dependent individuals (Fiellin and O'Connor, 2002).”
BackgroundOpioid Dependence Treatment and Guidelines
Nicholls, L., Bragaw, L., & Ruetsch, C. R. (2010) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2010.16.s1-b.14 · Cited by 83
Turner, B. J., Laine, C. M., Lin, Y., & Lynch, K. G. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1769 · Cited by 70
“7 Patient volume (visits/wk) Low (20-128)‡ 59 (23.”
Sayre, M., Lapham, G. T., Lee, A. K., Oliver, M. M., Bobb, J. F., Caldeiro, R. M., & Bradley, K. A. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05650-3 · Cited by 74
Predictive Factors for Relapse in Patients on Buprenorphine Maintenance
Ferri, M., Finlayson, A. J. R., Wang, L., & Martin, P. R. (2014) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12074.x · Cited by 66
BRIDGE, T. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00061-9 · Cited by 63
Miranda, A., & Taca, A. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2017.1295459 · Cited by 61
Buprenorphine treatment in an urban community health center: what to expect.
Cunningham, C. O., Giovanniello, A., Sacajiu, G. M., Whitley, S. D., Mund, P. A., Beil, R., & Sohler, N. (2008) · PubMed · Cited by 67
Manhapra, A., Quinones, L., & Rosenheck, R. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.12.035 · Cited by 68
Cunningham, C. O., Sohler, N., McCoy, K., & Kunins, H. V. (2006) · PubMed · Cited by 65
Public Health Behind Bars: From Prisons to Communities
Heath, M. (2007) · Springer eBooks · doi:10.1007/978-0-387-71695-4 · Cited by 72
Methods of Detoxification and Their Role in Treating Patients With Opioid Dependence
O’Connor, P. G. (2005) · JAMA · doi:10.1001/jama.294.8.961 · Cited by 69
Self-citationModels for Integrating Buprenorphine Therapy into the Primary HIV Care Setting
Basu, S., Smith-Rohrberg, D., Bruce, R. D., & Altice, F. L. (2006) · Clinical Infectious Diseases · doi:10.1086/500200 · Cited by 58
“Buprenorphine maintenance therapy has shown impressive efficacy against opiate dependence when used in office-based settings; there are few examples of the provision of buprenorphine maintenance therapy by HIV care providers [2, 12, 13], but buprenorphine maintenance therapy has been shown to improve adherence to HAAR…”
BackgroundSullivan, L. E., & Fiellin, D. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432888 · Cited by 58
“In the United States, physicians can receive a special registration to prescribe buprenorphine by becoming certified in addiction medicine or by completing 8 h of training in the treatment of opioid dependence [ 21 , 22]”
BackgroundSelf-citationNew Systems of Care for Substance Use Disorders
Pating, D., Miller, M. M., Goplerud, E. N., Martin, J., & Ziedonis, D. M. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.03.004 · Cited by 58
Variations in addiction: The molecular and the molar in neuroscience and pain medicine
Keane, H., & Hamill, K. (2010) · BioSocieties · doi:10.1057/biosoc.2009.4 · Cited by 55
Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013
Turner, L. W., Kruszewski, S. P., & Alexander, G. C. (2014) · American Journal on Addictions · doi:10.1111/ajad.12174 · Cited by 54
Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years.
Gordon, A., Trafton, J. A., Saxon, A., Gifford, A., Goodman, F., Calabrese, V. S., McNicholas, L., & Liberto, J. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.03.010 · Cited by 46
Morgan, O. W., Griffiths, C., & Hickman, M. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl207 · Cited by 49
Bruce, R. D., Moody, D. E., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.18 · Cited by 51
Methadone medical maintenance in primary care
Merrill, J. O., Jackson, T. R., Schulman, B. A., Saxon, A. J., Awan, A., Kapitan, S., Carney, M., Brumback, L. C., & Donovan, D. M. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.04028.x · Cited by 45
“In the United States, initial treatment may be provided by trained and certified physicians using buprenorphine, a new medication recently approved by the FDA for treatment of opioid dependence.(33) The reduced regulatory burden that applies to buprenorphine compared with methadone medical maintenance may make it more…”
Schuman-Olivier, Z., Borodovsky, J. T., Steinkamp, J., Munir, Q., Butler, K., Greene, M. A., Goldblatt, J., Xie, H. Y., & Marsch, L. A. (2018) · Addiction Science & Clinical Practice · doi:10.1186/s13722-018-0122-4 · Cited by 44
Altice, F. L., Sullivan, L. E., Smith-Rohrberg, D., Basu, S., Stancliff, S., & Eldred, L. J. (2006) · Clinical Infectious Diseases · doi:10.1086/508181 · Cited by 44
“Many of the studies demonstrating the effectiveness of either BMT or MMT in treating opioid dependence have been conducted primarily among individuals without other comorbid conditions, such as severe mental illness and hepatitis C virus infection [4, 77].”
BackgroundMedication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users
Bruce, R. D., Kresina, T. F., & McCance‐Katz, E. F. (2010) · AIDS · doi:10.1097/qad.0b013e32833407d3 · Cited by 44
“The second important difference is that buprenorphine has a higher binding affinity and occupies more receptor sites than methadone [15,16].”
BackgroundGordon, A. J., Liberto, J. C., Granda, S. E., Salmon‐Cox, S., Andrée, T., & McNicholas, L. F. (2008) · American Journal on Addictions · doi:10.1080/10550490802408613 · Cited by 42
Heroin anticraving medications: a systematic review
Fareed, A., Vayalapalli, S., Casarella, J., Amar, R., & Drexler, K. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.505991 · Cited by 41
On-site medical care in methadone maintenance: Associations with health care use and expenditures
Gourevitch, M. N., Chatterji, P., Deb, N., Schoenbaum, E. E., & Turner, B. J. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.07.008 · Cited by 43
Improving Public Health Through Access to and Utilization of Medication Assisted Treatment
Kresina, T. F., & Lubran, R. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8104102 · Cited by 43
“Models to implement buprenorphine in HIV clinical settings have also been piloted [37].”
BackgroundSmith-Rohrberg, D., Bruce, R. D., & Altice, F. L. (2004) · Journal of Drug Issues · doi:10.1177/002204260403400210 · Cited by 38
“As a partial agonist, there is a plateau of its agonist effects at higher doses that enhances its safety profile compared to full agonists and reduces its likelihood for street diversion (Fiellin & O’Connor, 2002; Ling & Smith, 2002).”
Ventricular arrhythmias in patients treated with methadone for opioid dependence
Hanon, S., Seewald, R., Yang, F., Schweitzer, P., & Rosman, J. Z. (2010) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-009-9465-9 · Cited by 36
“Many studies and decades of clinical experience support methadone’s efficacy as a treatment for opioid dependence [ 1 , 13].”
BackgroundCampbell, A. N. C., McCarty, D. W., Rieckmann, T. R., McNeely, J., Rotrosen, J., Wu, L.-T. T., & Bart, G. B. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.11.005 · Cited by 37
Evaluation of a Combined Online and in Person Training in the Use of Buprenorphine
Gunderson, E. W., LEVIN, F. R., Kleber, H. D., Fiellin, D. A., & Sullivan, L. E. (2006) · Substance Abuse · doi:10.1300/j465v27n03_06 · Cited by 33
“Since eight hours of instruction fulfills only the minimal training requirement under DATA 2000, it previously has been expected that physicians would benefit from additional training, including experience with opioid-dependent patientsonbuprenorphine(10).”
BackgroundSelf-citationLee, C. S., Liebschutz, J. M., Anderson, B. J., & Stein, M. D. (2017) · American Journal on Addictions · doi:10.1111/ajad.12533 · Cited by 35
Tilhou, A. S., Dague, L., Saloner, B. K., Beemon, D., & Burns, M. E. (2022) · JAMA Health Forum · doi:10.1001/jamahealthforum.2022.0093 · Cited by 32
Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients
Stella, L., D'Ambra, C., Mazzeo, F., Capuano, A., Franco, F. D., Avolio, A., & Ambrosino, F. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.036 · Cited by 32
Methadone and oral health--a brief review.
Brondani, M., & Park, P. E. (2011) · PubMed · Cited by 44
The role of adherence in tuberculosis HIV‐positive patients treated in ambulatory regimen
Rocha, M., Pereira, S., Ferreira, L., & Barros, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00077302 · Cited by 30
“The dose of methadone seems important for the retention of subjects in treatment programmes, with even low doses (20 mg) superior to nonmaintenance detoxification treatment, while moderate (40–50 mg) and particularly high (80–100 mg) daily doses associated with greater retention in treatment programmes [ 21 , 22].”
BackgroundBruce, R. D., & Altice, F. L. (2007) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990701653875 · Cited by 28
“Buprenorphine (BUP), a partial mu-opioid agonist, has a plateau of its agonist effects at higher doses, such as respiratory depression (3, 4), which improves its safety profile compared to methadone (5, 7).”
BackgroundLee, C. S., Rosales, R., Stein, M. D., Nicholls, M. E., O’Connor, B. M., Ryan, V. L., & Davis, E. A. (2019) · American Journal on Addictions · doi:10.1111/ajad.12925 · Cited by 26
Chang, E. T., Oberman, R. S., Cohen, A. N., Taylor, S. L., Gumm, E., Mardian, A. S., Toy, S., Revote, A., Lewkowitz, B., & Yano, E. M. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06255-6 · Cited by 27
Adherence to antiretroviral therapy: An update of current concepts
Lucas, G. M., Wu, A. W., & Cheever, L. W. (2004) · Current HIV/AIDS Reports · doi:10.1007/s11904-004-0027-6 · Cited by 24
Bruce, R. D., Altice, F. L., Moody, D. E., Lin, S.-N., Fang, W. B., Sabo, J. P., Wruck, J. M., Piliero, P. J., Conner, C., Andrews, L., et al. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.007 · Cited by 22
Management of opioid dependence
van den Brink, W., Goppel, M., & van Ree, J. M. (2003) · Current Opinion in Psychiatry · doi:10.1097/00001504-200305000-00005 · Cited by 24
Doorley, S., Ho, C. J., Echeverria, E., Preston, C., Ngo, H., Kamal, A., & Cunningham, C. (2016) · Substance Abuse · doi:10.1080/08897077.2016.1264535 · Cited by 20
Office-Based Opioid Dependence Treatment
Colson, J. D., Helm, S., & Silverman, S. M. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es231 · Cited by 19
Lundgren, L., Sullivan, L., & Amodeo, M. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.10.007 · Cited by 18
Fiellin, D. A., O’Connor, P. G., Chawarski, M. C., & Schottenfeld, R. S. (2004) · American Journal on Addictions · doi:10.1080/10550490490440843 · Cited by 16
Self-citationGuideline Development for Office-Based Pharmacotherapies for Opioid Dependence
Fiellin, D. A., & Barthwell, A. G. (2003) · Journal of Addictive Diseases · doi:10.1300/j069v22n04_09 · Cited by 16
Self-citationTreatment of Addiction in the Elderly
Clay, S. W. (2010) · Aging Health · doi:10.2217/ahe.10.14 · Cited by 16
McCarty, D. W., Gu, Y., Renfro, S., Baker, R., Lind, B. K., & McConnell, K. J. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.08.002 · Cited by 15
Buprenorphine for office-based treatment of patients with opioid addiction.
Manlandro, J. J. (2005) · PubMed · Cited by 14
Advances in the treatment of opioid use disorders
WOODY, G. E. (2017) · F1000Research · doi:10.12688/f1000research.10184.1 · Cited by 15
Psychosocial Interventions in Office-Based Opioid Treatment: A Systematic Review
Zerden, L. D. S., Guan, T., Lombardi, B. M., Sharma, A., & Garcia-Rico, Y. (2020) · Journal of the Society for Social Work and Research · doi:10.1086/708369 · Cited by 16
Implementing Group Visits for Opioid Use Disorder: A Case Series
Sokol, R., Albanese, M., Albanese, C., Coste, G., Grossman, E., Morrill, D., Roll, D., Sobieszczyk, A., & Schuman-Olivier, Z. (2020) · Substance Abuse · doi:10.1080/08897077.2019.1635958 · Cited by 12
Factors Determining How Early Adopter Physicians Use Buprenorphine in Treatment
Reif, S., Parks, C. L., & Wallack, S. S. (2007) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31814c3fa8 · Cited by 12
Disciplinary careers of drug-impaired physicians
Holtman, M. C. (2006) · Social Science & Medicine · doi:10.1016/j.socscimed.2006.09.016 · Cited by 11
Metadata
- Authors
- Fiellin, D. A., & O'Connor, P. G.
- Affiliations
- Yale University (US)
- ORCID
- Fiellin, David A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-09-12
- Volume
- 347
- Issue
- 11
- Pages
- 817-823
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2092853006
- Cited by
- 148
- References
- 36
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 4 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 4
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K12DA000167)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, heroin use, office-based treatment, methadone maintenance treatment, opioid detoxification, opioid use disorder treatment
- MeSH terms
- Adult, Drug and Narcotic Control, Heroin Dependence, Humans, Male, Methadone, Opioid-Related Disorders, Narcotics, Rehabilitation, United States, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.